תבנית:תרופה/זולדרוניק טבע 4 מ"ג/5 מ"ל - Zoledronic teva 4mg/5ml
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | *Zoledronic acid AS MONOHYDRATE 4 MG/VIAL âM05BA08
|
| צ×רת ××ª× | I.V |
| צ×רת ××× ×× | CONCENTRATE FOR SOLUTION FOR INFUSION |
| ×ת×××× | Treatment of hypercalcaemia of malignancy. Treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/××××ר×× ×ק ×××¢ 4 ×"×/5 ×"× - Zoledronic teva 4mg/5ml | |
| ×ת××ת ××× ×× | Posology and method of administration |
| ×ת××××ת × ×× | Contraindications |
| ת×פע×ת ××××× | Undesirable effects |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× | |
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××ר×× ×ק ×××¢ 4 ×"×/5 ×"× Â® ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL |
| ×©× ××¢× ×ר×ש×× | ABIC MARKETING LTD |
| ר×ש××× | ת×ר×× ××ש×: 07/2013. ר×ש××× ×ת×ר××: 11/2013 |
| ת×ר×× ×¢×××× ××ר×× | 21/08/17 |
ת××× ×ª ×ר×××
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: 5ml
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/5ml}}
×:
{{תר×פ×/5ml
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־21 באוגוסט 2017 ב־14:24